Dec 20, Sino Biopharm announces that the Group has entered into an exclusive sales agreement of Penpulimab monoclonal antibody with its associate CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. and the associate’s shareholder Akeso Biopharma Co., Ltd. Pursuant to the agreement, (i) the Group is authorized to be the sole sales agent of Penpulimab monoclonal antibody injection (PD-1 antibody (AK105) product, the “PD-1 Monoclonal Antibody Product”) in China, and is fully responsible for the market development and product promotion and sales of the PD-1 Monoclonal Antibody Product; and (ii) the Group will receive sales and marketing fees from CTTQ-Akeso, and procure the PD-1 Monoclonal Antibody Product from CTTQ-Akeso.

The PD-1 Monoclonal Antibody Product is co-developed by the Group and Akeso Biopharma, and has been granted marketing approval by the National Medical Products Administration of China, for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma after at least secondline systemic chemotherapy treatment. The entering into the exclusive sales agreement for Penpulimab monoclonal antibody will enable the PD-1 Monoclonal Antibody Product to take full advantage of the Group’s nationwide sales network and resources as well as its extensive experience in product promotion, which will be conducive to accelerating the commercialization of the PD-1 Monoclonal Antibody Product, benefitting more patients in China.